Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer

10.15252/emmm.201707945

Saved in:

Bibliographic Details
Main Authors:	Tsui, D.W.Y, Murtaza, M, Wong, A.S.C, Rueda, O.M, Smith, C.G, Chandrananda, D, Soo, R.A, Lim, H.L, Goh, B.C, Caldas, C, Forshew, T, Gale, D, Liu, W, Morris, J, Marass, F, Eisen, T, Chin, T.M, Rosenfeld, N
Other Authors:	MEDICINE
Format:	Article
Published:	2020
Subjects:	circulating tumor DNA epidermal growth factor receptor gefitinib hydroxychloroquine phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase antineoplastic agent DNA EGFR protein, human protein p53 TP53 protein, human Article cancer patient clinical article controlled study drug response EGFR gene gene gene dosage gene mutation human longitudinal study molecularly targeted therapy non small cell lung cancer overall survival PIK3CA gene priority journal progression free survival PTEN gene tumor suppressor gene whole genome sequencing blood chemistry copy number variation dna mutational analysis drug resistance genetics lung tumor mutation pathology prognosis survival analysis treatment outcome Antineoplastic Agents Carcinoma, Non-Small-Cell Lung DNA Copy Number Variations DNA Mutational Analysis DNA, Neoplasm Drug Resistance, Neoplasm ErbB Receptors Gefitinib Humans Hydroxychloroquine Longitudinal Studies Lung Neoplasms Mutation Prognosis Survival Analysis Treatment Outcome Tumor Suppressor Protein p53
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/178087
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-178087
record_format	dspace
spelling	sg-nus-scholar.10635-1780872024-04-18T03:09:36Z Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer Tsui, D.W.Y Murtaza, M Wong, A.S.C Rueda, O.M Smith, C.G Chandrananda, D Soo, R.A Lim, H.L Goh, B.C Caldas, C Forshew, T Gale, D Liu, W Morris, J Marass, F Eisen, T Chin, T.M Rosenfeld, N MEDICINE CANCER SCIENCE INSTITUTE OF SINGAPORE PHARMACOLOGY circulating tumor DNA epidermal growth factor receptor gefitinib hydroxychloroquine phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase antineoplastic agent DNA EGFR protein, human epidermal growth factor receptor gefitinib hydroxychloroquine protein p53 TP53 protein, human Article cancer patient clinical article controlled study drug response EGFR gene gene gene dosage gene mutation human longitudinal study molecularly targeted therapy non small cell lung cancer overall survival PIK3CA gene priority journal progression free survival PTEN gene tumor suppressor gene whole genome sequencing blood chemistry copy number variation dna mutational analysis drug resistance genetics lung tumor mutation non small cell lung cancer pathology prognosis survival analysis treatment outcome Antineoplastic Agents Carcinoma, Non-Small-Cell Lung DNA Copy Number Variations DNA Mutational Analysis DNA, Neoplasm Drug Resistance, Neoplasm ErbB Receptors Gefitinib Humans Hydroxychloroquine Longitudinal Studies Lung Neoplasms Mutation Prognosis Survival Analysis Treatment Outcome Tumor Suppressor Protein p53 10.15252/emmm.201707945 EMBO Molecular Medicine 10 6 e7945 2020-10-20T05:03:29Z 2020-10-20T05:03:29Z 2018 Article Tsui, D.W.Y, Murtaza, M, Wong, A.S.C, Rueda, O.M, Smith, C.G, Chandrananda, D, Soo, R.A, Lim, H.L, Goh, B.C, Caldas, C, Forshew, T, Gale, D, Liu, W, Morris, J, Marass, F, Eisen, T, Chin, T.M, Rosenfeld, N (2018). Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. EMBO Molecular Medicine 10 (6) : e7945. ScholarBank@NUS Repository. https://doi.org/10.15252/emmm.201707945 17574676 https://scholarbank.nus.edu.sg/handle/10635/178087 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	circulating tumor DNA epidermal growth factor receptor gefitinib hydroxychloroquine phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase antineoplastic agent DNA EGFR protein, human epidermal growth factor receptor gefitinib hydroxychloroquine protein p53 TP53 protein, human Article cancer patient clinical article controlled study drug response EGFR gene gene gene dosage gene mutation human longitudinal study molecularly targeted therapy non small cell lung cancer overall survival PIK3CA gene priority journal progression free survival PTEN gene tumor suppressor gene whole genome sequencing blood chemistry copy number variation dna mutational analysis drug resistance genetics lung tumor mutation non small cell lung cancer pathology prognosis survival analysis treatment outcome Antineoplastic Agents Carcinoma, Non-Small-Cell Lung DNA Copy Number Variations DNA Mutational Analysis DNA, Neoplasm Drug Resistance, Neoplasm ErbB Receptors Gefitinib Humans Hydroxychloroquine Longitudinal Studies Lung Neoplasms Mutation Prognosis Survival Analysis Treatment Outcome Tumor Suppressor Protein p53
spellingShingle	circulating tumor DNA epidermal growth factor receptor gefitinib hydroxychloroquine phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase antineoplastic agent DNA EGFR protein, human epidermal growth factor receptor gefitinib hydroxychloroquine protein p53 TP53 protein, human Article cancer patient clinical article controlled study drug response EGFR gene gene gene dosage gene mutation human longitudinal study molecularly targeted therapy non small cell lung cancer overall survival PIK3CA gene priority journal progression free survival PTEN gene tumor suppressor gene whole genome sequencing blood chemistry copy number variation dna mutational analysis drug resistance genetics lung tumor mutation non small cell lung cancer pathology prognosis survival analysis treatment outcome Antineoplastic Agents Carcinoma, Non-Small-Cell Lung DNA Copy Number Variations DNA Mutational Analysis DNA, Neoplasm Drug Resistance, Neoplasm ErbB Receptors Gefitinib Humans Hydroxychloroquine Longitudinal Studies Lung Neoplasms Mutation Prognosis Survival Analysis Treatment Outcome Tumor Suppressor Protein p53 Tsui, D.W.Y Murtaza, M Wong, A.S.C Rueda, O.M Smith, C.G Chandrananda, D Soo, R.A Lim, H.L Goh, B.C Caldas, C Forshew, T Gale, D Liu, W Morris, J Marass, F Eisen, T Chin, T.M Rosenfeld, N Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
description	10.15252/emmm.201707945
author2	MEDICINE
author_facet	MEDICINE Tsui, D.W.Y Murtaza, M Wong, A.S.C Rueda, O.M Smith, C.G Chandrananda, D Soo, R.A Lim, H.L Goh, B.C Caldas, C Forshew, T Gale, D Liu, W Morris, J Marass, F Eisen, T Chin, T.M Rosenfeld, N
format	Article
author	Tsui, D.W.Y Murtaza, M Wong, A.S.C Rueda, O.M Smith, C.G Chandrananda, D Soo, R.A Lim, H.L Goh, B.C Caldas, C Forshew, T Gale, D Liu, W Morris, J Marass, F Eisen, T Chin, T.M Rosenfeld, N
author_sort	Tsui, D.W.Y
title	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
title_short	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
title_full	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
title_fullStr	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
title_full_unstemmed	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
title_sort	dynamics of multiple resistance mechanisms in plasma dna during egfr-targeted therapies in non-small cell lung cancer
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/178087
_version_	1800914474989780992

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer

Similar Items